An announcement from Nuvation Bio ( (NUVB) ) is now available.
On February 12, 2025, Dr. Jerry Wang, CEO of AnHeart Therapeutics, a subsidiary of Nuvation Bio Inc., departed the company after achieving key goals, including regulatory approvals for taletrectinib in China and the U.S., and the integration of AnHeart Therapeutics post-merger. Dr. Wang’s departure was not due to any disagreements, and his role as CEO was deemed unnecessary following these accomplishments.
More about Nuvation Bio
Nuvation Bio Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of novel therapeutic candidates for the treatment of cancer. The company has a specific market focus on advanced ROS1-positive non-small cell lung cancer (NSCLC).
YTD Price Performance: -13.90%
Average Trading Volume: 2,534,647
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $769.7M
For an in-depth examination of NUVB stock, go to TipRanks’ Stock Analysis page.